 |
| (사진=휴젤) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Hugel made an announcement on the 4th that 50 units and 100 units of "Letybo," a botulinum toxin formulation, obtained approval from the U.S. Food and Drug Administration (FDA) on the 29th of last month (local time).
The entry of botulinum toxin into the United States is the second domestic company after Daewoong Pharmaceutical's Nabota, and the seventh case in the US market as a whole.
Also, with this entry into the US market, Hugel became the first domestic company and the third global company to sell toxin products to the US, China, and Europe, the world's top three toxin markets.
Hugel has been approved by the demanding US FDA, demonstrating the competitiveness and reliability of the product and further enhancing the company's global leadership.
Hugel is finalizing its entry strategy with the goal of launching products in the US market in the middle of this year. As Letybo was launched in Canada last year and laid the groundwork for entering North America, it is expected that the US will accelerate.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
